Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients | WAPE

Newsbenzinga

AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients

Jun 12, 2026, 10:30 ET · Published

Article summary

AbbVie says nine-year CLL14 data showed longer progression-free survival with venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

An excerpt from the original article.

Related companies

ABBVABBVView stock

Comments —

Comment

Loading comments…